Objectives: Supplementation of purified n-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has been shown to reduce cardiovascular risk beyond low-density lipoprotein cholesterol (LDL-C). However, regarding the circulating levels of PUFAs, despite anti-atherogenic features of EPA, there is controversy about those of DHA. In this study, we aimed to clarify the difference in the clinical association with atherogenic or anti-atherogenic lipoproteins between circulating EPA and DHA levels.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2014 Published by Elsevier Inc.